BioXcel's BXCL501 Data In Dementia Patients Reinforce Its Efficacy In Agitation
Company Plans Phase III Discussions In H1 2021
Executive Summary
Execs said data from the institutional setting could be a bridge to other settings, while the duration of response indicates a real-world benefit that could aid adoption.
You may also be interested in...
BioXcel Turns To Commercialization With Positive Phase III Data In Agitation
The company is developing a sublingual thin film of dexmedetomidine that could be used to treat agitation in a wide range of indications after planned initial launches in schizophrenia and bipolar disorder.
Humanigen Takes Aim At IL-6 Inhibitors With CRS Drug Lenzilumab
Roche's Actemra is a major player in this space, but Humanigen is looking to take it on directly.
Gritstone Jumps Into COVID-19 Vaccine Race, Eyeing Mutant Strains
The company is developing a vaccine with both adenoviral and mRNA technology that could potentially overcome resistance mutations on the SARS-CoV-2 spike protein.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports